Craig Crews Is Elected as an AACR Fellow

Craig Crews is being recognized for “excellence in drug discovery and development spanning from molecule to patient and for his work on pharmacological modulation of protein turnover. Combining groundbreaking science with strong entrepreneurship, he has spearheaded new and revolutionary therapeutic approaches including the development of novel proteasome inhibitors and proteolysis targeting chimera (PROTAC) technology, enabling the drugging of cancer targets previously considered undruggable.”  

Congratulations Craig!  

Click here to learn more